Edwards Lifesciences Investments increased by 6.2% to $241.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 52.1%, from $158.80M to $241.50M. Over 5 years (FY 2020 to FY 2025), Investments shows an upward trend with a 45.3% CAGR.
An increase suggests strategic expansion or capital deployment into partnerships, while a decrease may indicate divestitures or impairment.
Represents the carrying value of long-term investments in unconsolidated entities, joint ventures, or minority interests...
Varies significantly based on the company's M&A strategy and reliance on joint ventures versus wholly-owned operations.
non_current_assets_investments_in_affiliates_subsidiarie_2849e6| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $81.60M | $82.00M | $92.50M | $92.10M | $99.90M | $108.90M | $108.30M | $111.10M | $110.40M | $109.80M | $121.20M | $122.80M | $123.60M | $144.60M | $159.40M | $158.80M | $206.50M | $207.90M | $227.30M | $241.50M |
| QoQ Change | — | +0.5% | +12.8% | -0.4% | +8.5% | +9.0% | -0.6% | +2.6% | -0.6% | -0.5% | +10.4% | +1.3% | +0.7% | +17.0% | +10.2% | -0.4% | +30.0% | +0.7% | +9.3% | +6.2% |
| YoY Change | — | — | — | — | +22.4% | +32.8% | +17.1% | +20.6% | +10.5% | +0.8% | +11.9% | +10.5% | +12.0% | +31.7% | +31.5% | +29.3% | +67.1% | +43.8% | +42.6% | +52.1% |